RayKnowChina Research Map
Shortlist

Blood disorders

Lymphoma in Shanghai

上海 淋巴瘤

All diseases in Shanghai

20 hospitals in Shanghai

Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shanghai may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 97 papers led
  2. 35 papers led
  3. 33 papers led
  4. 23 papers led
  5. 22 papers led
  6. 18 papers led
  7. 16 papers led
  8. 14 papers led
  9. 11 papers led
    No open trial led
  10. 11 papers led
  11. 10 papers led
    No open trial led
  12. 9 papers led
    No open trial led
  13. 7 papers led
    No open trial led
  14. 7 papers led
    No open trial led
  15. 6 papers led
    No open trial led
  16. 6 papers led
    No open trial led
  17. 5 papers led
    No open trial led
  18. 1 paper led
    No open trial led
  19. 0 papers led
    No open trial led
  20. 0 papers led
    No open trial led

Lymphoma in every city Shanghai on the disease page, with the national map

157

open trials on lymphoma with a hospital in Shanghai

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shanghai as lead sponsor or study site. 93 of them are led by a hospital in Shanghai. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Phase
    Phase 4
    Started
    2026-03
    Posted
    Registry
    NCT07218341

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou

  2. Recruiting
    Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07300514

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  3. Recruiting
    T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07353840

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  4. Recruiting
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07380984

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  5. Recruiting
    Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07381738

    Age 14 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  6. Recruiting
    A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
    Phase
    Phase 2/Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07389616

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  7. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  8. Recruiting
    Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07414758

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai General HospitalShanghai

  9. Recruiting
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07496229

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  10. Recruiting
    Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07502768

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  11. Recruiting
    Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07507318

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  12. Recruiting
    The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07514169

    Age 70 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  13. Recruiting
    A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07519772

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou

  14. Recruiting
    A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07570017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  15. Recruiting
    A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07606937

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin

  16. Recruiting
    A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07628738

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  17. Recruiting
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07634471

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  18. Recruiting
    BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07678229

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  19. Recruiting
    Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07727083

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  20. Recruiting
    Exploration of Circular RNA in B-cell Hematologic Malignancies
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07774572

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  21. Recruiting
    A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07823829

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai, Wuhan

  22. Recruiting
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06717347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen

  23. Recruiting
    A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06742996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  24. Recruiting
    POLA-R-CHP in the First-line Treatment of Transformed DLBCL
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06743945

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  25. Recruiting
    MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06793189

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesBeijing, Shanghai, Shenyang

  26. Recruiting
    Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06803693

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  27. Recruiting
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06829771

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou

  28. Recruiting
    Newly-diagnosed Pediatric T-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06855810

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan

  29. Recruiting
    CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06925464

    Age 14 years to 70 years (registered criteria)

    Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai

  30. Recruiting
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06943872

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou

  31. Recruiting
    Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06967038

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalShanghai

  32. Recruiting
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06973187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou

  33. Recruiting
    Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06987916

    Age 2 years to 75 years (registered criteria)

    Led by Tongji HospitalShanghai

  34. Recruiting
    Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07001540

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  35. Recruiting
    RGL-305+ Lymphoma + Exploratory Clinical Study
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT07006012

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  36. Recruiting
    Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07012980

    Age 70 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  37. Recruiting
    CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07022964

    Age 14 years to 70 years (registered criteria)

    Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai

  38. Recruiting
    A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07053670

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 1 listed hospital as study siteShanghai, Wuhan

  39. Recruiting
    Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07070648

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  40. Recruiting
    A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT07072169

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  41. Recruiting
    The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07073833

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai

  42. Recruiting
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07082686

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  43. Recruiting
    Clinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT07093073

    Age 2 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  44. Recruiting
    Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
    Phase
    Early phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07162012

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  45. Recruiting
    Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
    Phase
    Phase 2/Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07168980

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  46. Recruiting
    Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07185373

    Age 18 years to 75 years (registered criteria)

    Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou

  47. Recruiting
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07188610

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  48. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  49. Recruiting
    A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA)
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07191431

    Age 14 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  50. Recruiting
    Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07199296

    Age 14 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  51. Recruiting
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07200375

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou

  52. Recruiting
    Universal CAR-T Cell Therapy for NHL
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT07248163

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalShanghai

  53. Recruiting
    Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07253129

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  54. Recruiting
    Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07270861

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  55. Recruiting
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07272499

    Age 14 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  56. Recruiting
    T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07470996

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  57. Recruiting
    Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
    Phase
    Phase 4
    Started
    2025-10
    Posted
    Registry
    NCT07934537

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalShanghai

  58. Recruiting
    A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06219356

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou

  59. Recruiting
    Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06228963

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  60. Recruiting
    Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06314334

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai

  61. Recruiting
    A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06341556

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  62. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  63. Recruiting
    CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06365671

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  64. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  65. Recruiting
    Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06445517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin

  66. Recruiting
    CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06445803

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai

  67. Recruiting
    A Cohort Study in Newly Diagnosed MZL
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06449885

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  68. Recruiting
    Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06484985

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai

  69. Recruiting
    A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06494371

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  70. Recruiting
    Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06496308

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  71. Recruiting
    An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06517004

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  72. Recruiting
    Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06517511

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shanghai

  73. Recruiting
    Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06519526

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  74. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  75. Recruiting
    The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06522555

    Age 70 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  76. Recruiting
    Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06534463

    Age 14 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  77. Recruiting
    Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06541327

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  78. Recruiting
    Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
    Phase
    Phase 2/Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06563245

    Age 2 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  79. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06566586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  80. Recruiting
    BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06598722

    Age 18 years to 60 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  81. Recruiting
    Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06686108

    Age 14 years to 55 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  82. Recruiting
    A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06734871

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  83. Recruiting
    PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06755775

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  84. Recruiting
    CD70-targeted immunoPET Imaging of Malignant Cancers
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06852638

    Age 18 years to 80 years (registered criteria)

    Led by Renji HospitalShanghai

  85. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  86. Recruiting
    Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
    Phase
    Not given
    Started
    2024-02
    Posted
    Registry
    NCT07236203

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  87. Recruiting
    Genotype-guided Treatment in Newly Diagnosed PTCL
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05675813

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  88. Recruiting
    Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
    Phase
    Phase 3
    Started
    2023-02
    Posted
    Registry
    NCT05681260

    Age 12 months to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai

  89. Recruiting
    Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05698147

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou

  90. Recruiting
    Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05768529

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou

  91. Recruiting
    A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05800977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou

  92. Recruiting
    Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
    Phase
    Phase 4
    Started
    2023-05
    Posted
    Registry
    NCT05806580

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  93. Recruiting
    Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-01
    Posted
    Registry
    NCT05842707

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  94. Recruiting
    A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT05899621

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  95. Recruiting
    Real-World Study of DLBCL With Different Genetic Subtypes
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT06026488

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  96. Recruiting
    PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06069830

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  97. Recruiting
    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06082102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou

  98. Recruiting
    A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT06084936

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou

  99. Recruiting
    A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06136351

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  100. Recruiting
    CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
    Phase
    Phase 1
    Started
    2023-08
    Posted
    Registry
    NCT06136364

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  101. Recruiting
    The Pathogenesis and Prognostic Factors of Lymphoma
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT06203652

    Age not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  102. Recruiting
    The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06503276

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Ninth People's HospitalShanghai

  103. Recruiting
    Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06876688

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

  104. Recruiting
    Cell Free DNA in Mature B-cell Lymphoma
    Phase
    Not given
    Started
    2022-09
    Posted
    Registry
    NCT04088422

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  105. Recruiting
    A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
    Phase
    Phase 2/Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05139017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou

  106. Recruiting
    A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Phase
    Phase 3
    Started
    2022-07
    Posted
    Registry
    NCT05254743

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan

  107. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  108. Recruiting
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04728893

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  109. Recruiting
    A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT05006716

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou

  110. Recruiting
    The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
    Phase
    Phase 3
    Started
    2021-09
    Posted
    Registry
    NCT05018520

    Age 14 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  111. Recruiting
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
    Phase
    Phase 1
    Started
    2021-03
    Posted
    Registry
    NCT06189391

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou

  112. Recruiting
    A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2021-10
    Posted
    Registry
    NCT06725524

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  113. Recruiting
    Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    Phase
    Phase 2
    Started
    2020-01
    Posted
    Registry
    NCT03936153

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou

  114. Recruiting
    Evaluate the Safety and Clinical Activity of HH2853
    Phase
    Phase 1/Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04390737

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

  115. Recruiting
    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 1/Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04494503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan

  116. Recruiting
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 2
    Started
    2020-10
    Posted
    Registry
    NCT04586478

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou

  117. Recruiting
    Phase Ib Clinical Study of Keynatinib
    Phase
    Phase 1
    Started
    2020-09
    Posted
    Registry
    NCT04807881

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Chengdu, Shanghai

  118. Recruiting
    Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
    Phase
    Not given
    Started
    2013-06
    Posted
    Registry
    NCT06795113

    Age 18 years to 100 years (registered criteria)

    Led by Ruijin HospitalShanghai

  119. Not yet recruiting
    A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT06970496

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Wenzhou, Xi'an

  120. Not yet recruiting
    Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07334574

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  121. Not yet recruiting
    Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07405255

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  122. Not yet recruiting
    A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07511114

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  123. Not yet recruiting
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07535710

    Age 60 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  124. Not yet recruiting
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07535762

    Age 65 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  125. Not yet recruiting
    The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07548255

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  126. Not yet recruiting
    A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07583771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  127. Not yet recruiting
    AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07594899

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  128. Not yet recruiting
    LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07602322

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  129. Not yet recruiting
    Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07613788

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  130. Not yet recruiting
    Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07638787

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  131. Not yet recruiting
    A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07705308

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesShanghai

  132. Not yet recruiting
    New Genotype-guided Treatment in Newly Diagnosed PTCL
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07706959

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  133. Not yet recruiting
    Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
    Phase
    Phase 2/Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07712588

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Chongqing, Harbin, Shanghai

  134. Not yet recruiting
    AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07717177

    Age 70 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  135. Not yet recruiting
    A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07719855

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  136. Not yet recruiting
    GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07768943

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  137. Not yet recruiting
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07784101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  138. Not yet recruiting
    Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07812493

    Age 14 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  139. Not yet recruiting
    A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07855016

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  140. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  141. Not yet recruiting
    Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07945353

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  142. Not yet recruiting
    The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06747299

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  143. Not yet recruiting
    Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06788600

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  144. Not yet recruiting
    The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06863441

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  145. Not yet recruiting
    Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06935136

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  146. Not yet recruiting
    Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07122609

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  147. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

  148. Not yet recruiting
    The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-02
    Posted
    Registry
    NCT06255795

    Age 14 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  149. Not yet recruiting
    Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06549335

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  150. Not yet recruiting
    JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06567080

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  151. Not yet recruiting
    CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06567366

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  152. Not yet recruiting
    ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06646666

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  153. Not yet recruiting
    The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06656234

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  154. Not yet recruiting
    Real World Study of Linperlisib for Lymphoma Treatment
    Phase
    Not given
    Started
    2023-05
    Posted
    Registry
    NCT05863871

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 1 listed hospital as study siteShanghai, Tianjin

  155. Not yet recruiting
    Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06062641

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  156. Enrolling by invitation
    Real-world Study of Acalabrutinib
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06767891

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  157. Enrolling by invitation
    Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT07450040

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Shanghai

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Shanghai, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Cancer Hospital, Fudan Universitynonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Changhai Hospital海军军医大学第一附属医院(长海医院)2221 open19315 open201 open8812 open101 open7none2none110nonenonenonenonenone9nonenonenonenonenonenone01 opennonenonenonenone417none1none2nonenonenonenonenonenone1none1nonenonenone1none001none0nonenonenonenone
Changzheng Hospital海军军医大学第二附属医院(长征医院)none3151 open171 open4041 opennone10nonenone516402262 opennonenonenone6nonenonenone1nonenonenonenonenonenonenone5none81nonenone2none0nonenonenonenone1none5nonenone21nonenonenonenonenone1nonenonenonenone
Child Health Hospitalnonenonenonenonenonenone26nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone8nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children Hospital, Fudan Universitynonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital of Fudan University复旦大学附属儿科医院nonenonenonenonenonenonenone115004none111none0none0501 opennone1nonenonenonenone12none213 open5372 open310nonenonenonenone311 open021021none1none1042none0none10none
Dahua Hospitalnonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
East Hospital上海市东方医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Eastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院)nonenone2144 open6none7nonenonenonenonenone41nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone00nonenonenonenonenonenonenonenonenone
Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院324 opennonenonenonenonenonenonenonenone63 open0nonenone51 opennonenonenonenonenone161 opennonenonenonenonenonenonenonenonenonenonenonenone17nonenone0nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenone
Fengxian District Central Hospital上海市奉贤区中心医院none3nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fifth People's Hospital of Fudan University复旦大学附属上海市第五人民医院nonenonenonenonenone2nonenonenonenone11nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Naval Medical Universitynonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Rehabilitation Hospital, Tongji University上海市第一康复医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院381 open328 open542 open8817 open24331 open21211 open39090 open15nonenone360none4none0nonenone3318 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Gongli Hospital上海市浦东新区公利医院nonenonenonenonenonenonenonenonenonenonenone00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangming Traditional Chinese Medicine Hospital上海市浦东新区光明中医医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Gynecology Hospital, Fudan University复旦大学附属妇产科医院nonenonenonenonenonenone17nonenonenonenone0none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Health Sciences Affiliated Zhoupu Hospital上海市浦东新区周浦医院nonenonenonenonenonenonenonenonenonenonenone111nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Huadong Hospital, Fudan University复旦大学附属华东医院none11 opennone41 open42111 opennonenonenonenonenone0nonenonenonenonenonenone06nonenonenonenonenonenonenonenone2nonenone14nonenonenonenonenone0none0nonenonenonenone24none1nonenonenonenonenone1nonenonenonenonenonenonenonenone
Huashan Hospital复旦大学附属华山医院none12621 open226 open62191 open261 open1226 opennonenone420105nonenonenone351 opennone1nonenonenone231 open0314 open17nonenone53none1nonenone7none1011none111none6nonenonenone00nonenone21nonenonenonenonenone
Infant Hospital上海市第一妇婴保健院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone30nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiading District Anting Hospital上海市嘉定区安亭医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiahui International Hospital上海嘉会国际医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jing'an District Centre Hospital上海市静安区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jinshan Hospital, Fudan University复旦大学附属金山医院nonenonenonenonenonenonenonenonenonenonenone5none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone
Longhua Hospital上海中医药大学附属龙华医院none7111344none36nonenonenone14none1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone51 opennone2nonenonenone1nonenonenonenonenonenonenonenone1nonenonenone20nonenonenonenone1nonenonenonenone
Minhang Hospital上海市闵行区中心医院nonenonenone9nonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Putuo Hospital上海市普陀区中心医院nonenonenonenonenonenonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Renji Hospital上海交通大学医学院附属仁济医院22 open81 open1045 open655 open883 open1037 open7620 open251 open3113102none242 opennonenone3232 opennonenone1nonenone111 open231 opennonenone31110020none0none3none1none02none6nonenonenone171 open5nonenonenone2nonenonenonenonenone
Ruijin Hospital上海交通大学医学院附属瑞金医院none221 open353 open9613 open6811 open11418 open11518 open14nonenonenone131 open22022114 opennone29755 open05none0nonenonenonenone2nonenone594 open211nonenone02203nonenonenone142 opennonenonenone0nonenonenonenonenone2nonenonenonenone
Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine上海市第七人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Baoshan Luodian Hospital上海市宝山区罗店医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Chest Hospital上海市胸科医院none4012 opennonenone41445 opennonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone114nonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Children's Hospital上海市儿童医院nonenonenonenonenonenonenonenonenonenonenone1none61none1none1none40nonenonenonenonenonenonenonenone1none102nonenonenonenonenonenonenonenonenone20000nonenonenonenone2nonenonenonenonenonenonenonenone
Shanghai Children's Medical Center上海交通大学医学院附属上海儿童医学中心nonenonenonenonenonenonenonenone171 opennonenone0none110none81 open5none110nonenonenone2nonenonenonenonenonenonenone971 open2nonenonenonenonenonenone00002 opennonenone30nonenonenonenone221nonenonenonenonenonenone
Shanghai East Hospital, Tongji University同济大学附属东方医院1133637502 open125013none01222113nonenonenone7nonenonenonenone1nonenonenonenonenonenone201 open11nonenonenonenone4none11 opennonenonenonenonenonenone1nonenonenone0nonenonenonenonenonenonenonenonenonenone
Shanghai Eighth People Hospital上海市第八人民医院nonenonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Electric Power Hospital上海电力医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Fengxian District Central Hospitalnonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Fourth People's Hospital同济大学附属上海市第四人民医院nonenonenonenonenonenonenonenone1nonenone1nonenonenone31 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai General Hospital上海市第一人民医院53361 open271 open494 open357 open6213none152420none200none118 opennone0nonenonenonenonenonenonenonenonenone254none11none1none1nonenonenonenonenonenone0nonenonenonenone0nonenonenonenonenone2nonenonenone
Shanghai Jiading Central Hospital上海市嘉定区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Shanghai Mengchao Cancer Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Mental Health Center上海市精神卫生中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Municipal Hospital, Shanghai University of Traditional Chinese Medicine上海市中医医院nonenonenonenone28nonenonenonenonenonenone2none10nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenone11nonenonenonenonenonenonenonenonenone
Shanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院54nonenone3311279none29none1512nonenonenonenonenone221 opennone1nonenone1nonenonenonenonenonenone1502none0none4nonenone0nonenone11none0nonenone10nonenone01nonenone1nonenonenone
Shanghai Proton and Heavy Ion Center上海市质子重离子医院0none2none63 open01 open13 open2nonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pudong Hospital上海市浦东医院nonenonenonenonenone2106none0none0nonenonenone10nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pudong New Area People's Hospital上海市浦东新区人民医院nonenonenonenonenonenonenonenonenonenonenone0none00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pulmonary Hospital上海市肺科医院none5nonenone39443 opennonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone71 opennonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Putuo District Liqun Hospital上海市普陀区利群医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Sixth People's Hospital上海市第六人民医院3027214315438nonenone0350411nonenonenonenonenonenonenonenonenone2nonenonenonenonenone112nonenonenonenone2none4nonenonenone0none00nonenone711nonenonenonenone0nonenonenonenone
Shanghai Songjiang District Central Hospital上海市松江区中心医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Stomatological Hospital上海市口腔医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Tenth People's Hospital上海市第十人民医院none32721611444123none0210205nonenonenone10nonenonenonenonenonenonenonenonenonenonenone27nonenonenone2none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Tong Ren Hospital上海市同仁医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Xuhui Central Hospital上海徐汇中心医院nonenonenonenonenonenonenonenone1nonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenone
Shibei Hospital上海市静安区市北医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shuguang Hospital上海中医药大学附属曙光医院nonenone20nonenonenonenonenonenonenonenone1none00nonenonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenone2nonenonenone3nonenonenonenonenonenonenonenone3nonenonenone11nonenonenonenonenonenonenonenonenone
Tongji Hospital同济大学附属同济医院none3none1730nonenone9nonenonenone212none21 open01 open0none185 opennonenonenonenonenonenonenonenonenonenonenone92nonenonenonenone2none0nonenonenonenone0none0nonenonenonenone0nonenonenonenonenonenonenonenonenone
Xinhua Hospital上海交通大学医学院附属新华医院nonenone21243212283215none401702nonenonenone7nonenonenonenonenonenonenone2none297363 open330nonenone0none10100001 open221 open1010364nonenonenonenonenonenone
Xinshijie Zhongxing Eye Hospital上海新视界中兴眼科医院nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yangpu Hospital上海市杨浦区中心医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yangzhi Rehabilitation Hospital, Tongji University上海市养志康复医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine上海中医药大学附属岳阳中西医结合医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone1nonenonenonenone1nonenonenonenone
Zhabei Central Hospital上海市静安区闸北中心医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenone7nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhongshan Hospital, Fudan University复旦大学附属中山医院3568 open40816 open1348 open1864 open779 open441 open193none052802234 opennonenonenone142 open1nonenonenonenone0411 opennonenonenone10914 open30none0332 opennone313nonenonenone12none4nonenone10nonenonenone1none0nonenonenonenone
Zhongshan-Xuhui Hospital上海市徐汇区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Shanghai.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lymphoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shanghai on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data